Insmed (FRA:IM8N) Future 3-5Y EPS without NRI Growth Rate : 23.09 (As of Dec. 14, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Insmed Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Insmed's Future 3-5Y EPS without NRI Growth Rate is 23.09.

Competitive Comparison of Insmed's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Insmed's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insmed's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Insmed's Future 3-5Y EPS without NRI Growth Rate falls into.

Insmed (FRA:IM8N) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Insmed Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Insmed's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

INSM:USA 0JAV:UK IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Headlines

No Headlines